Scarica l'app Stockscreener
12.09
1.43%
0.17
Dopo l'orario di chiusura:
12.01
-0.08
-0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Combining price and volume data for Astria Therapeutics Inc.Entry Point & AI Forecasted Entry/Exit Points - newser.com
This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
ATXS Downgraded to Neutral by HC Wainwright & Co. | ATXS Stock N - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - cnhinews.com
Automated trading signals detected on Astria Therapeutics Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - newser.com
Institutional scanner results for Astria Therapeutics Inc.2025 Short Interest & Consistent Profit Alerts - newser.com
Identifying reversal signals in Astria Therapeutics Inc.July 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
ATXS Faces Downgrade with Price Target Slashed by Analyst Wedbush | ATXS Stock News - GuruFocus
BioCryst Keen To Take Takeda’s HAE Crown With Astria Acquisition - insights.citeline.com
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - Yahoo Finance
Astria Therapeutics (ATXS) Downgraded by JMP Securities: Latest Analyst Insights | ATXS Stock News - GuruFocus
Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition - Seeking Alpha
BioCryst to buy Astria Therapeutics for $700m in enterprise value - Pharmaceutical Technology
How the Astria Deal Is Shaping the New Story for BioCryst Pharmaceuticals - Yahoo Finance
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com Canada
Astria Therapeutics (ATXS) Acquisition Sparks Interest in Naveni - GuruFocus
Low frequency sounds good to Biocryst in $700M Astria HAE buy - BioWorld MedTech
Astria Therapeutics (ATXS) Acquisition Boosts Confidence in BioC - GuruFocus
Form 425 Astria Therapeutics, Filed by: BIOCRYST PHARMACEUTICALS INC - StreetInsider
ATXS Rating Downgraded: Jefferies Lowers Price Target | ATXS Sto - GuruFocus
BioCryst to Acquire Astria in $700M Deal - USA Herald
Covington, Sidley Guide $700M BioCryst Allergic Disease Deal - Law360
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings - Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc. for approximately $720 million. - MarketScreener
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - cnhinews.com
Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks
BioCryst to Acquire Astria Therapeutics in $700 Million Deal - contractpharma.com
BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On TuesdayAmerican Resources (NASDAQ:AREC), Albertsons Companies (NYSE:ACI) - Benzinga
ATXS Stocks Flying High: Too Late to Buy? - StocksToTrade
BioCryst To Acquire Astria Therapeutics - citybiz
BioCryst Pharmaceuticals To Acquire Astria In $700 Million Deal - Finimize
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus
BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus
BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus
BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits
BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq
BioCryst to acquire Astria Therapeutics for $700 million - Investing.com
Astria Therapeutics (ATXS) Acquired by BioCryst in $700M Deal - GuruFocus
BioCryst to buy Astria Therapeutics in $700 million deal - Yahoo Finance
BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal - Nasdaq
Astria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst falls By Investing.com - Investing.com Canada
BioCryst Announces Merger with Astria Therapeutics - TipRanks
BioCryst to buy Astria Therapeutics for $13 per share - MSN
BioCryst to acquire Astria Therapeutics, strengthening presence in HAE, transforming growth profile - MarketScreener
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - The Manila Times
ATXS SEC FilingsAstria Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What to do if you’re stuck in Astria Therapeutics Inc.July 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Can Astria Therapeutics Inc. stock maintain operating margins2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
How to forecast Astria Therapeutics Inc. trends using time seriesMarket Risk Report & Real-Time Buy Signal Alerts - newser.com
Published on: 2025-10-14 01:02:46 - newser.com
BioCryst proposes Astria deal; S-4 and approvals to follow - Stock Titan
Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN
Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):